Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

FTH

Faeth Therapeutics Inc

26.70

Jul 08 • 01:09PM ET +0.59 (2.25%)

Healthcare Biotechnology USA Small NASD

Peers: BCTX CLRB JSPR LGVN MRKR NXTC PLUR TPST TRAW VTGN

| Held by: VXF IWC

Scroll to Statements

Index	-
Market Cap	688.25M
Enterprise Value	814.98M
Income	-184.46M
Sales	0.00M
Book/sh	-102.43
Cash/sh	7.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	29
IPO	Feb 04, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	3.39
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	14.39
Current Ratio	14.39
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-142.73
EPS next Y	-6.53
EPS next Q	-3.54
EPS this Y	-691.77%
EPS next Y	95.07%
EPS next 5Y	29.95%
EPS past 3/5Y	19.15% -4.83%
Sales past 3/5Y	- -
EPS Y/Y TTM	-518.34%
Sales Y/Y TTM	-
EPS Q/Q	-2312.30%
Sales Q/Q	-
Earnings	May 15 BMO
EPS/Sales Surpr.	-21101.61% -

Insider Own	17.77%
Insider Trans	0.51%
Inst Own	12.88%
Inst Trans	11.49%
ROA	-151.41%
ROE	-165.30%
ROIC	-96.48%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	32.81%
SMA50	29.50%
SMA200	53.98%
Trades

Shs Outstand	25.78M
Shs Float	21.20M
Short Float	3.77%
Short Ratio	13.35
Short Interest	0.80M
52W High	36.76 -27.37%
52W Low	6.32 322.11%
Volatility	12.69% 18.35%
ATR (14)	3.26
RSI (14)	65.62
Beta	-0.25
Rel Volume	1.84
Avg Volume	59.78K
Volume	64,309

Perf Week	6.79%
Perf Month	82.24%
Perf Quarter	-11.57%
Perf Half Y	174.39%
Perf YTD	150.22%
Perf Year	195.66%
Perf 3Y	7.65%
Perf 5Y	-84.05%
Perf 10Y	-
Recom	1.17
Target Price	54.40
Prev Close	26.11
Price	26.70
Change	2.25%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-26	Initiated	Robert W. Baird	Outperform	$57
Jun-22-26	Initiated	H.C. Wainwright	Buy	$60
Jun-11-26	Initiated	BTIG Research	Buy	$55
May-29-26	Initiated	Cantor Fitzgerald	Overweight
May-22-26	Initiated	Citigroup	Buy	$55
Apr-20-26	Initiated	Leerink Partners	Outperform	$50
Jun-02-25	Resumed	H.C. Wainwright	Buy	$5
May-14-24	Initiated	Stephens	Overweight	$5
Jul-01-21	Downgrade	Berenberg	Buy → Hold	$12
Jun-29-21	Downgrade	Oppenheimer	Outperform → Perform	$30 → $14
Mar-01-21	Initiated	Piper Sandler	Overweight	$25
Mar-01-21	Initiated	Oppenheimer	Outperform	$36
Mar-01-21	Initiated	Citigroup	Buy	$30
Mar-01-21	Initiated	Berenberg	Buy	$27

Show Previous Ratings

Jul-03-26 04:00PM	Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-15-26 08:10AM	Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer (Business Wire) +6.54%
Jun-04-26 04:00PM	Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -11.75%
May-15-26 07:30AM	Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (Business Wire)
May-05-26 07:30AM	Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer (Business Wire)
07:30AM	Loading…
Apr-09-26 07:30AM	Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-30-26 07:30AM	Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update (Business Wire) -9.21%
Mar-17-26 06:00AM	Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-26 06:00AM	Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-18-26 12:09PM	Sensei Biotherapeutics Stock Soars 230% After Faeth Deal (Benzinga) +187.51%
08:00AM	Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement (Business Wire)
Nov-14-25 07:30AM	Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire) -11.25%
Oct-31-25 02:06PM	Sensei to ditch its lead candidate and cut workforce amidst strategic review (Pharmaceutical Technology)
Oct-30-25 09:00AM	Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value (GlobeNewswire)
Oct-17-25 08:00AM	Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 (GlobeNewswire) -33.43%
07:30AM	Loading…
Sep-23-25 07:30AM	Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025 (GlobeNewswire)
Sep-03-25 08:00AM	Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +10.57%
Aug-05-25 07:30AM	Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-30-25 07:30AM	Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 (GlobeNewswire) +7.50%
Jun-13-25 07:30AM	Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -10.58%
May-06-25 07:30AM	Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress (GlobeNewswire) -5.29%
Apr-02-25 07:30AM	Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire) +6.09%
Mar-28-25 07:30AM	Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress (GlobeNewswire) +17.99%
Mar-27-25 04:05PM	Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors (GlobeNewswire)
Feb-06-25 12:00PM	What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock (Zacks)
Feb-04-25 07:30AM	Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-08-25 07:30AM	Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones (GlobeNewswire)
Nov-27-24 04:05PM	Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference (GlobeNewswire)
Nov-14-24 07:30AM	Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -13.06%
Oct-29-24 07:30AM	Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences (GlobeNewswire)
04:05PM	Loading…
Sep-04-24 04:05PM	Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference (GlobeNewswire)
07:30AM	Sensei Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Aug-06-24 01:53PM	SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024 (InvestorPlace) +6.56%
07:30AM	Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-30-24 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -11.07%
May-24-24 08:27AM	Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today? (InvestorPlace) -45.52%
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-23-24 05:10PM	Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 (GlobeNewswire) +6.62%
May-09-24 01:54PM	SNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024 (InvestorPlace) -14.67%
07:30AM	Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-24-24 04:05PM	Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-09-24 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference (GlobeNewswire) +6.28%
Apr-04-24 04:05PM	Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment (GlobeNewswire)
Mar-22-24 07:30AM	Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium (GlobeNewswire) +11.43%
Mar-06-24 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences (GlobeNewswire)
Feb-28-24 07:30AM	Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +9.09%
Feb-07-24 07:30AM	Sensei Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) +6.12%
Jan-04-24 07:30AM	Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones (GlobeNewswire)
Nov-07-23 08:09AM	Sensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Results (GuruFocus.com) -7.15%
07:30AM	Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-03-23 04:05PM	Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting (GlobeNewswire) -13.75% +9.42%
Nov-01-23 07:30AM	Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer (GlobeNewswire) +15.33%
Oct-25-23 09:05AM	Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting (GlobeNewswire)
Oct-23-23 07:30AM	Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023 (GlobeNewswire)
Sep-27-23 07:30AM	Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron s Libtayo (GlobeNewswire) -10.17%
Sep-21-23 07:30AM	Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference (GlobeNewswire)
Sep-13-23 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference (GlobeNewswire)
Aug-30-23 07:30AM	Sensei Biotherapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-03-23 07:30AM	Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-02-23 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuitys 43rd Annual Growth Conference (GlobeNewswire)
Jun-13-23 07:30AM	Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, A New Vista for Cancer Care: Exploring SNS-101s Potential as a Transformative Treatment Option for Patients with Solid Tumors (GlobeNewswire)
Jun-01-23 07:30AM	Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors (GlobeNewswire)
May-31-23 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-23 07:30AM	Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-20-23 07:30AM	Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody (GlobeNewswire)
Apr-18-23 04:05PM	Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire)
Apr-13-23 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuitys Horizons in Oncology Virtual Conference (GlobeNewswire)
Mar-30-23 07:30AM	Sensei Biotherapeutics to Participate in Cantor Fitzgeralds Future of Oncology Virtual Symposium (GlobeNewswire) +6.11%
Mar-28-23 07:30AM	Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-23-23 11:56AM	Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation (Simply Wall St.)
Mar-21-23 07:30AM	Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody (GlobeNewswire)
Mar-14-23 04:35PM	Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire) +9.92%
Mar-07-23 05:15PM	Sensei Biotherapeutics Adopts Stockholder Rights Agreement (GlobeNewswire) +6.49%
Mar-06-23 07:30AM	Sensei Biotherapeutics to Participate in Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-21-23 07:30AM	Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics (GlobeNewswire) -7.14%
Feb-16-23 07:30AM	Sensei Biotherapeutics to Participate in Citis 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-14-23 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics (GlobeNewswire)
Feb-06-23 07:30AM	Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody (GlobeNewswire)
Jan-05-23 07:30AM	Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors (GlobeNewswire)
Dec-08-22 01:10PM	Immunotherapy startup shutters Boston research site, lays off 17 (American City Business Journals)
10:40AM	Sensei Biotherapeutics Slashes Workforce, Closes R&D Site (Benzinga)
07:30AM	Sensei Biotherapeutics Provides Update on Strategic Priorities (GlobeNewswire)
Nov-22-22 07:30AM	Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-21-22 07:30AM	Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody (GlobeNewswire)
06:00AM	Significant Investor in Sensei Biotherapeutics, Inc. Urges Board to Seek Shareholder Mandate (GlobeNewswire)
Nov-10-22 09:00AM	Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) +9.49%
Nov-08-22 07:30AM	Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-07-22 07:30AM	Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint (GlobeNewswire)
Nov-02-22 07:30AM	Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference (GlobeNewswire)
Oct-14-22 10:22AM	We're Keeping An Eye On Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Rate (Simply Wall St.)
Oct-05-22 08:05AM	Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire)
Sep-30-22 04:05PM	Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival (GlobeNewswire) +7.10%
Sep-21-22 04:05PM	Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival (GlobeNewswire) -5.32%
Aug-31-22 07:30AM	Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody (GlobeNewswire)
Aug-23-22 07:30AM	Sensei Biotherapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-22 07:02AM	One Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insider upped their stake by 13% in the previous year (Simply Wall St.)
Aug-09-22 07:30AM	Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -5.37%
Jun-01-22 07:30AM	Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer (GlobeNewswire)
May-25-22 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference (GlobeNewswire) -6.32%

Faeth Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Senior VP of FinanceMr. Josiah Craver CPA

General Counsel & SecretaryMr. Christopher W. Gerry J.D.

J.D.Mr. Anand Parikh Esq.

Ph.D.Dr. Brian C. Stephenson C.F.A.

Vice President of Investor Relations & CommunicationsMs. Lora Pike

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STEPHENSON BRIAN C	Chief Financial Officer	Jun 30 '26	Buy	24.25	7,803	189,240	41,688	Jul 01 08:09 PM
STEPHENSON BRIAN C	Chief Financial Officer	Jul 01 '26	Buy	23.50	5,000	117,492	46,688	Jul 01 08:09 PM
STEPHENSON BRIAN C	Chief Financial Officer	Jun 29 '26	Buy	23.34	831	19,396	33,885	Jul 01 08:09 PM
STEPHENSON BRIAN C	Chief Financial Officer	Jun 24 '26	Buy	26.13	9,391	245,360	26,804	Jun 26 07:40 PM
STEPHENSON BRIAN C	Chief Financial Officer	Jun 26 '26	Buy	24.95	6,250	155,908	33,054	Jun 26 07:40 PM
STEPHENSON BRIAN C	Chief Financial Officer	Jun 23 '26	Buy	24.36	9,230	224,806	17,413	Jun 24 06:58 PM
STEPHENSON BRIAN C	Chief Financial Officer	Jun 22 '26	Buy	22.13	8,183	181,115	8,183	Jun 24 06:58 PM
Parikh Anand Kiran	President and CEO	Jun 22 '26	Option Exercise	1.16	53,465	62,019	817,699	Jun 24 06:55 PM
Parikh Anand Kiran	President and CEO	Jun 22 '26	Buy	19.76	2,806	55,447	764,234	Jun 24 06:55 PM
Cambrian BioPharma Inc	10% Owner	Jun 01 '26	Sale	20.02	25,000	500,543	130,142	Jun 01 05:21 PM
Peyer James	10% Owner	Jun 01 '26	Sale	20.02	25,000	500,543	130,142	Jun 01 05:20 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 02 '26	Buy	35.01	2,003	70,133	144,974	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 07 '26	Buy	33.38	1,108	36,985	133,986	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 06 '26	Buy	31.02	1,104	34,246	141,029	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 07 '26	Sale	31.01	8,151	252,775	133,986	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 02 '26	Sale	32.12	7,666	246,239	144,974	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 06 '26	Sale	31.06	1,259	39,100	141,029	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 01 '26	Buy	34.49	6,175	212,979	147,731	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 31 '26	Buy	28.16	6,005	169,121	146,657	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 31 '26	Sale	25.49	1,591	40,553	146,657	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 01 '26	Sale	31.65	1,150	36,396	147,731	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 27 '26	Buy	26.61	15,321	407,717	142,360	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 30 '26	Buy	25.86	9,533	246,495	145,678	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 26 '26	Buy	28.62	5,731	164,045	131,370	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 26 '26	Sale	28.12	1,857	52,220	131,370	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 30 '26	Sale	26.61	888	23,632	145,678	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 27 '26	Sale	26.81	505	13,538	142,360	May 15 04:22 PM
Cambrian BioPharma Inc	10% Owner	Apr 29 '26	Proposed Sale	31.95	155,142	4,956,786		Apr 29 03:26 PM
Celebi John	Former Officer	Feb 24 '26	Proposed Sale	34.49	3,374	116,356		Feb 24 04:11 PM
Peyer James	Fomer Director	Feb 18 '26	Proposed Sale	27.13	950	25,769		Feb 18 01:22 PM
RINGO WILLIAM R	Former Director	Jan 27 '26	Proposed Sale	9.83	1,169	11,486		Jan 27 05:33 PM
Cambrian BioPharma Inc	10% Owner	Dec 09 '25	Option Exercise	6.40	395	2,528	155,983	Dec 10 04:56 PM
Cambrian BioPharma Inc	10% Owner	Dec 09 '25	Sale	8.25	6,612	54,575	155,142	Dec 10 04:56 PM
Peyer James	10% Owner	Dec 09 '25	Option Exercise	6.40	395	2,528	155,983	Dec 10 04:52 PM
Peyer James	10% Owner	Dec 09 '25	Sale	7.96	3,507	27,903	155,142	Dec 10 04:52 PM
Peyer James	10% Owner	Dec 08 '25	Sale	8.59	3,105	26,672	158,254	Dec 10 04:52 PM
Peyer James	Former Director	Dec 09 '25	Proposed Sale	7.97	841	6,707		Dec 09 12:20 PM
Cambrian BioPharma Inc	10% Owner	Dec 05 '25	Sale	11.50	16,295	187,390	161,359	Dec 08 04:39 PM
Cambrian BioPharma Inc	10% Owner	Dec 04 '25	Sale	9.06	5,000	45,300	177,654	Dec 08 04:39 PM
Peyer James	10% Owner	Dec 05 '25	Sale	11.50	16,295	187,390	161,359	Dec 08 04:36 PM
Peyer James	10% Owner	Dec 04 '25	Sale	9.06	5,000	45,300	177,654	Dec 08 04:36 PM
Cambrian BioPharma Inc	10% Owner	Dec 04 '25	Proposed Sale	8.71	5,844	50,901		Dec 04 04:18 PM
Cambrian BioPharma Inc	10% Owner	Dec 04 '25	Proposed Sale	8.71	21,222	184,843		Dec 04 03:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FTH

Faeth Therapeutics Inc

Upgrade your Finviz experience